Study details
Enrolling now
GLP-1R Agonist Treatment for Opioid Use Disorder
Milton S. Hershey Medical Center
NCT IDNCT06548490ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
200
Study length
about 1.9 years
Ages
18–75
Locations
3 sites in MD, NY, PA
About this study
Researchers are testing if semaglutide, a medication, can reduce opioid use in adults receiving treatment for opioid use disorder. The trial will compare semaglutide to a placebo (a needle prick with no drug) over 686 days to see if semaglutide helps people refrain from using illicit and nonprescribed opioids.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take Semaglutide Pen Injector
PhasePhase 2
DrugSemaglutide Pen Injector
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
antidiabetic (GLP-1 agonist; stimulates insulin release)
Drug routes
oral (Oral Tablet)
Body systems
Psychiatry / Mental Health